Sepsis Diagnostic Market Research Report by Testing Type, Technology, Product, Method, Pathogen, End-user, Country - North America Forecast to 2027 - Cumulative Impact of COVID-19

The North America Sepsis Diagnostic Market size was estimated at USD 152.15 million in 2021 and expected to reach USD 165.75 million in 2022, and is projected to grow at a CAGR 9.61% to reach USD 263.95 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Sepsis Diagnostic to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Testing Type, the market was studied across Laboratory Testing and PoC Testing.

Based on Technology, the market was studied across Flow Cytometry, Immunoassays, Microbiology, and Molecular Diagnostics.

Based on Product, the market was studied across Assay Kits and Reagents, Blood Culture Media, Instruments, and Software.

Based on Method, the market was studied across Automated Diagnostics and Conventional Diagnostics.

Based on Pathogen, the market was studied across Bacterial Sepsis and Fungal Sepsis. The Bacterial Sepsis is further studied across Gram-Negative Bacteria and Gram-Positive Bacteria.

Based on End-user, the market was studied across Hospitals, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes.

Based on Country, the market was studied across Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Sepsis Diagnostic market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Sepsis Diagnostic Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the North America Sepsis Diagnostic Market, including Abbott Laboratories, Alifax S.r.l., Beckman Coulter, Inc., Becton, Dickinson and Company, bioMérieux SA, Boditech Med Inc., Bruker Corporation, Cerner Corporation, CytoSorbents Corporation, EKF Diagnostics, Epic Systems Corporation, F. Hoffmann-La Roche AG, GenMark Diagnostics, Immunexpress Inc., Koninklijke Philips N.V., Luminex Corporation, McKesson Corporation, Response Biomedical Corporation, Seegene Inc., Thermo Fisher Scientific, Inc., and Wolters Kluwer N.V..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the North America Sepsis Diagnostic Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the North America Sepsis Diagnostic Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the North America Sepsis Diagnostic Market?
4. What is the competitive strategic window for opportunities in the North America Sepsis Diagnostic Market?
5. What are the technology trends and regulatory frameworks in the North America Sepsis Diagnostic Market?
6. What is the market share of the leading vendors in the North America Sepsis Diagnostic Market?
7. What modes and strategic moves are considered suitable for entering the North America Sepsis Diagnostic Market?

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Sepsis Diagnostic Market, by Testing Type
6.1. Introduction
6.2. Laboratory Testing
6.3. PoC Testing

7. Sepsis Diagnostic Market, by Technology
7.1. Introduction
7.2. Flow Cytometry
7.3. Immunoassays
7.4. Microbiology
7.5. Molecular Diagnostics

8. Sepsis Diagnostic Market, by Product
8.1. Introduction
8.2. Assay Kits and Reagents
8.3. Blood Culture Media
8.4. Instruments
8.5. Software

9. Sepsis Diagnostic Market, by Method
9.1. Introduction
9.2. Automated Diagnostics
9.3. Conventional Diagnostics

10. Sepsis Diagnostic Market, by Pathogen
10.1. Introduction
10.2. Bacterial Sepsis
10.3.1. Gram-Negative Bacteria
10.3.2. Gram-Positive Bacteria
10.3. Fungal Sepsis

11. Sepsis Diagnostic Market, by End-user
11.1. Introduction
11.2. Hospitals
11.3. Pathology & Reference Laboratories
11.4. Research Laboratories & Academic Institutes

12. Canada Sepsis Diagnostic Market
12.1. Introduction

13. Mexico Sepsis Diagnostic Market
13.1. Introduction

14. United States Sepsis Diagnostic Market
14.1. Introduction

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. Abbott Laboratories
16.1.1. Business Overview
16.1.2. Key Executives
16.1.3. Product & Services
16.2. Alifax S.r.l.
16.2.1. Business Overview
16.2.2. Key Executives
16.2.3. Product & Services
16.3. Beckman Coulter, Inc.
16.3.1. Business Overview
16.3.2. Key Executives
16.3.3. Product & Services
16.4. Becton, Dickinson and Company
16.4.1. Business Overview
16.4.2. Key Executives
16.4.3. Product & Services
16.5. bioMérieux SA
16.5.1. Business Overview
16.5.2. Key Executives
16.5.3. Product & Services
16.6. Boditech Med Inc.
16.6.1. Business Overview
16.6.2. Key Executives
16.6.3. Product & Services
16.7. Bruker Corporation
16.7.1. Business Overview
16.7.2. Key Executives
16.7.3. Product & Services
16.8. Cerner Corporation
16.8.1. Business Overview
16.8.2. Key Executives
16.8.3. Product & Services
16.9. CytoSorbents Corporation
16.9.1. Business Overview
16.9.2. Key Executives
16.9.3. Product & Services
16.10. EKF Diagnostics
16.10.1. Business Overview
16.10.2. Key Executives
16.10.3. Product & Services
16.11. Epic Systems Corporation
16.11.1. Business Overview
16.11.2. Key Executives
16.11.3. Product & Services
16.12. F. Hoffmann-La Roche AG
16.12.1. Business Overview
16.12.2. Key Executives
16.12.3. Product & Services
16.13. GenMark Diagnostics
16.13.1. Business Overview
16.13.2. Key Executives
16.13.3. Product & Services
16.14. Immunexpress Inc.
16.14.1. Business Overview
16.14.2. Key Executives
16.14.3. Product & Services
16.15. Koninklijke Philips N.V.
16.15.1. Business Overview
16.15.2. Key Executives
16.15.3. Product & Services
16.16. Luminex Corporation
16.16.1. Business Overview
16.16.2. Key Executives
16.16.3. Product & Services
16.17. McKesson Corporation
16.17.1. Business Overview
16.17.2. Key Executives
16.17.3. Product & Services
16.18. Response Biomedical Corporation
16.18.1. Business Overview
16.18.2. Key Executives
16.18.3. Product & Services
16.19. Seegene Inc.
16.19.1. Business Overview
16.19.2. Key Executives
16.19.3. Product & Services
16.20. Thermo Fisher Scientific, Inc.
16.20.1. Business Overview
16.20.2. Key Executives
16.20.3. Product & Services
16.21. Wolters Kluwer N.V.
16.21.1. Business Overview
16.21.2. Key Executives
16.21.3. Product & Services

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing